Opana IR Pediatric Labeling Supplement Faces US FDA Panel Review

 
• By Sue Sutter
  
Children-drug-danger
Pediatric labeling for opioids will be the AdComm's focus. • Source: Shutterstock

More from US FDA Performance Tracker

More from Regulatory Trackers